Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Dan Gallagher is a columnist for The Wall Street Journal’s Heard on the Street, where he covers the technology and media industries. His work for the Heard column spans the businesses of artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback